FGL2 and central nervous system cancer: Expression of FGL2 by glioma cells leads to the suppression of the dendritic cell marker CD103 by blocking granulocyte macrophage colony-stimulating factor (GM-CSF), which in turn leads to defective differentiation of DCs.